No Data
No Data
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Most Popular Amongst Private Companies Who Own 46%, While Individual Investors Hold 34%
Baiyunshan (00874): Tianxin Pharmaceutical's injection of cefpirome hydrochloride (0.5g, 1.0g) passed the generic drug consistency evaluation.
Baiyunshan (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (hereinafter referred to as...
Baiyunshan (600332.SH): Subsidiaries' pharmaceutical products pass the evaluation of generic drug consistency.
GeLonghui August 23rd | Baiyunshan (600332.SH) announced that its holding subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (referred to as "Tianxin Pharmaceutical") has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The injection of Cefpirome Hydrochloride (0.5g, 1.0g) has passed the generic drug quality and efficacy consistency evaluation. Cefpirome is a fourth-generation cephalosporin antibiotic, which can be used to treat moderate to severe infections caused by sensitive bacteria in adults and children aged 2 months to 16 years old.
Guangzhou Baiyunshan Secures Marketing Authorization for Compound Acetaminophen Granules
Baiyunshan (00874.HK) plans to hold a board of directors meeting on August 30 to approve its interim performance.
Baiyunshan (00874.HK) announced on August 16th that the board of directors will hold a meeting on Friday, August 30th, 2024 to review and approve the unaudited financial performance of the company and its subsidiaries for the six months ended June 30th, 2024, and to handle other matters (if any).
Baiyunshan (600332.SH): Pharmaceutical Application Supplementary Approval for Compound Paracetamol and Chlorpheniramine Maleate Granules Obtained.
Baiyunshan (600332.SH) announced on August 16th that its wholly-owned subsidiary Guangxi Baiyunshan Yingkang Pharmaceutical Co., Ltd. received the Approval Notice for Drug Supplement Application issued by the National Medical Products Administration. Compound Paracetamol and Chlorphenamine Maleate Granules have undergone the application for change of the holder of the drug marketing license, and have obtained the approval of the National Medical Products Administration for the relevant changes. Compound Paracetamol and Chlorphenamine Maleate Granules are used to relieve symptoms such as fever, headache, nasal congestion, and sneezing caused by common colds and influenza.
No Data